A Trial of PT2977 in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
An open-label Phase 2 study of PT2977 in combination with cabozantinib in patients with advanced ccRCC.
A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma
- ClinicalTrials.gov Identifier: NCT03634540
- Protocol Number: 18-415
- Principal Investigator: David McDermott
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required